Shanghai Moyom Biotechnology Co. Ltd. has launched its Aphranel Magiccrystal dermal filler, the first injectable calcium hydroxylapatite microsphere-based dermal filler developed in China, and the company is already expanding globally.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: BDC Laboratories, Dialcare, Exact Sciences, Freenome, GE Healthcare, Gentuity, Helix, Nanovibronix, Orchestra Biomed, Reshape Lifesciences, Veracyte, Vyome, Zelis.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Instylla, Surgibox, Zien Medical.
A management-led syndicate of prominent investors acquired a majority stake in Histosonics Inc. that values the company at approximately $2.25 billion. The funding will support expansion of the Edison Histotripsy system and therapy platform into new clinical indications and markets. Edison uses non-invasive focused ultrasound energy to destroy tumors.
The U.S. Federal Trade Commission (FTC) reported Aug. 6 that it will try to block Edwards Lifesciences Corp.’s proposed acquisition of Jenavalve because Edwards’ acquisition of both Jenavalve Technology Inc. and JC Medical would eliminate competition in the TAVR space for aortic regurgitation.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Bionano, Bridge to Life, Caredx, Implantica, Paragonix.
RSS
